CYP17A1抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08201(CYP17A1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P08201(CYP17A1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The CYP17A1 antibody is a crucial tool in studying the cytochrome P450 17A1 enzyme, a key player in steroid hormone biosynthesis. CYP17A1. located in the endoplasmic reticulum, exhibits dual enzymatic activities: 17α-hydroxylase and 17.20-lyase. These functions enable it to catalyze the conversion of pregnenolone and progesterone to 17α-hydroxypregnenolone and 17α-hydroxyprogesterone (precursors for glucocorticoids and androgens) and subsequently to dehydroepiandrosterone (DHEA) and androstenedione, respectively. This enzyme is primarily expressed in adrenal glands, gonads, and placenta, making it vital for cortisol, estrogen, and androgen production.

Antibodies targeting CYP17A1 are widely used in research and diagnostics to localize its expression in tissues, quantify protein levels via techniques like immunohistochemistry, Western blotting, or ELISA, and investigate disorders linked to its dysfunction. For instance, CYP17A1 deficiency causes congenital adrenal hyperplasia (17α-hydroxylase deficiency), leading to hypertension and sexual development abnormalities. Conversely, its overexpression in certain cancers (e.g., prostate, adrenal tumors) has spurred interest in therapeutic targeting. Drugs like abiraterone, a CYP17A1 inhibitor, are used to treat advanced prostate cancer by suppressing androgen synthesis.

These antibodies also aid in elucidating regulatory mechanisms of steroidogenesis and evaluating pharmacological interventions, bridging molecular insights with clinical applications.